Product Description
Adalimumab injection is used to treat the symptoms and prevent the progression of active rheumatoid arthritis and ankylosing spondylitis. It is used in children 2 years of age and older for juvenile idiopathic arthritis.
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, France, Germany, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Slovakia, Spain, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 25
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Juvenile|Arthritis, Psoriatic|Arthritis, Rheumatoid|Colitis, Ulcerative|Dupuytren Contracture|Enthesopathy|Psoriasis|Spondylitis, Ankylosing
Phase 2: Inflammatory Bowel Diseases|Pain Unspecified
Phase 1: Arthritis, Infectious|Axial Spondyloarthritis|Behcet Syndrome|COVID-19|Crohn Disease|Healthy Volunteers|Hidradenitis Suppurativa|Oncology Unspecified|Uveitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BCD-057-5 | P1 |
Recruiting |
Healthy Volunteers|Oncology Unspecified |
2025-11-01 |
88% |
2025-10-04 |
Patient Enrollment|Primary Endpoints|Treatments |
| NCT06291948 | P1 |
Completed |
Arthritis, Psoriatic|Arthritis, Rheumatoid|Behcet Syndrome|Colitis, Ulcerative|Axial Spondyloarthritis|Arthritis, Infectious|Psoriasis|Crohn Disease|Spondylitis, Ankylosing|Hidradenitis Suppurativa|Uveitis |
2023-01-10 |
2024-03-05 |
Primary Endpoints |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
COVID-19 |
2022-03-01 |
|||
| STRATIFY | P2 |
Recruiting |
Inflammatory Bowel Diseases|Arthritis, Rheumatoid |
2026-03-01 |
12% |
2025-08-20 |
Primary Completion Date|Primary Endpoints|Start Date |
| HUM-OA | P2 |
Completed |
Pain Unspecified |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| KnaPsAck | P3 |
Recruiting |
Arthritis, Juvenile|Arthritis, Psoriatic |
2026-09-01 |
31% |
2024-12-27 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
| M10-870 | P3 |
Completed |
Colitis, Ulcerative |
2025-04-08 |
81% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| S67402 | P3 |
Active, not recruiting |
Dupuytren Contracture |
2025-03-18 |
2025-05-02 |
Treatments |
|
| MABPS-3/2020 | P3 |
Recruiting |
Psoriasis |
2025-03-01 |
33% |
2023-11-30 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| I1F-MC-RHCG | P3 |
Active, not recruiting |
Arthritis, Juvenile|Arthritis, Psoriatic|Enthesopathy|Spondylitis, Ankylosing |
2024-02-19 |
40% |
2025-06-06 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments |
| TIGERS | P2 |
Active, not recruiting |
Arthritis, Psoriatic |
2022-10-28 |
2022-03-13 |
Treatments |
|
| PIMOC | P2 |
Active, not recruiting |
Unknown |
None |
2022-03-13 |
Treatments |
|
| IM101-863 | P3 |
Active, not recruiting |
Arthritis, Rheumatoid |
2023-06-14 |
42% |
2024-10-16 |
Primary Endpoints |
| CTR20201600 | P3 |
Completed |
Spondylitis, Ankylosing |
2023-04-15 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20200016 | P3 |
Active, not recruiting |
Psoriasis|Spondylitis, Ankylosing|Arthritis, Rheumatoid |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| CTR20190112 | P3 |
Active, not recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| CTR20202167 | P3 |
Active, not recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| M10-870 | P3 |
Completed |
Colitis, Ulcerative |
2025-04-08 |
2025-05-02 |
Treatments |
|
| SOLOMON-I | P1 |
Recruiting |
Healthy Volunteers |
2026-02-01 |
50% |
2025-06-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| CHS-1420-10 | P1 |
Completed |
Healthy Volunteers |
2025-05-06 |
2025-08-30 |
Primary Endpoints|Treatments |
|
| CTR20180539 | P1 |
Completed |
Arthritis, Rheumatoid|Psoriasis|Spondylitis, Ankylosing |
2023-09-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| CR109299 | P1 |
Completed |
Healthy Volunteers |
2023-08-01 |
4% |
2023-08-22 |
Primary Completion Date|Primary Endpoints |
| CTR20200020 | P1 |
Completed |
Spondylitis, Ankylosing|Arthritis, Rheumatoid|Psoriasis |
2023-04-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| 2021-006015-29 | P3 |
Completed |
Psoriasis |
2023-10-19 |
47% |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
| ADA-IJZ-3001 | P3 |
Completed |
Psoriasis |
2023-09-19 |
47% |
2024-10-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |